Rethinking about Effect of Adjuvant Chemotherapy for Older Breast Cancer Patients_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 呂青 , 陳潔

Corresponding?author：

呂青, Email: lqlq1963@163.com

Keywords：

老年患者; 乳腺癌; 輔助化療

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 呂青,陳潔. Rethinking about Effect of Adjuvant Chemotherapy for Older Breast Cancer Patients. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2013, 20(8): 833-837. doi: Copy

1.	Yancik R， Ries LA. Aging and cancer in America. Demographic and epidemiologic perspectives[J]. Hematol Oncol Clin North Am， 2000， 14(1)：17-23.
2.	Hickey M， Peate M， Saunders CM， et al. Breast cancer in young women and its impact on reproductive function[J]. Hum Reprod Update， 2009， 15(3)：323-339.
3.	中國廣播網. 中國第六次人口普查[EB/OL]. http：//native. cnr. cn/list/201208/t20120810_510541842. html.
4.	Althuis MD， Dozier JM， Anderson WF， et al. Global trends inbreast cancer incidence and mortality 1973-1997[J]. Int J Epid-emiol， 2005， 34(2)：405-412.
5.	NCCN. Clinical Practice Guidelines in Oncology (NCCN Guidelines)-Breast Cancer[EB/OL]. http：//www.nccn. com/cancer-guidelines. html.
6.	Brunello A， Basso U， Pogliani C， et al. Adjuvant chemotherapy for elderly patients (＞or=70 years) with early high-risk breast cancer：a retrospective analysis of 260 patients[J]. Ann Oncol， 2005， 16(8)：1276-1282.
7.	應紅艷，白春梅，管梅，等. 老年乳腺癌患者的臨床病理特點及治療影響因素[J]. 中國醫學科學院學報， 2010， 32(4)：398-402.
8.	Holmes CE， Muss HB. Diagnosis and treatment of breast cancer in the elderly[J]. CA Cancer J Clin， 2003， 53(4)：227-244.
9.	Office for National Statistics 2010-based period expectation of life， 1981-2060. United Kingdom：Principal Projection[EB/OL].http：//www. ons. gov. uk/ons/publications/re-referencetables. html?edition=tcm%3A77-227587.
10.	新年齡分段[EB/OL]. http：//baike. baidu. com/view/10593790. htm.
11.	Muss HB， Berry DA， Cirrincione CT， et al. Adjuvant chemotherapy in older women with early-stage breast cancer[J]. N Engl J Med， 2009， 360(20)：2055-2065.
12.	Muss HB， Woolf S， Berry D， et al. Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer[J]. JAMA， 2005， 293(9)：1073-1081.
13.	Singh R， Hellman S， Heimann R. The natural history of breast carcinoma in the elderly：implications for screening and treatment[J]. Cancer， 2004， 100(9)：1807-1813.
14.	Jung SP， Lee JE， Lee SK， et al. Adjuvant chemotherapy and survival of elderly korean patients with breast carcinoma[J]. J Breast Cancer， 2012， 15(3)：296-305.
15.	Fargeot P， Bonneterre J， Roché H， et al. Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable， node-positive， elderly breast cancer patients：6-year follow-up results of the French adjuvant study group 08 trial[J]. J Clin Oncol， 2004， 22(23)：4622-4630.
16.	Biganzoli L， Wildiers H， Oakman C， et al. Management of elderlypatients with breast cancer：updated recommendations of the Intern-ational Society of Geriatric Oncology (SIOG) and European Societyof Breast Cancer Specialists (EUSOMA)[J]. Lancet Oncol， 2012， 13(4)：148-160.
17.	Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival：an overview of the randomised trials[J]. Lancet， 2005， 365(9472)：1687-1717.
18.	Giordano SH， Duan Z， Kuo YF， et al. Use and outcomes of adjuvant chemotherapy in older women with breast cancer[J]. J Clin Oncol， 2006， 24(18)：2750-2756.
19.	Elkin EB， Hurria A， Mitra N， et al. Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer：assessing outcome in a population-based， observational cohort[J]. J Clin Oncol， 2006， 24(18)：2757-2764.
20.	Debled M， Bellera C， Donamaria C， et al. Chemotherapy treatment for older women with metastatic breast cancer：what is the evidence?[J]. Cancer Treat Rev， 2011， 37(8)：590-598.
21.	Jones S， Holmes FA， O’Shaughnessy J， et al. Docetaxel withcyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide：7-year follow-up of US Oncology Research Trial 9735[J]. J Clin Oncol， 2009，.
22.	Ladoire S， Rambach L， Quipourt V， et al. Feasibility and safety of weekly sequential epirubicin-paclitaxel as adjuvant treatment for operable breast cancer patients older than 70 years[J]. Clin Breast Cancer， 2011， 11(4)：235-240.
23.	(2)：130-137.
24.	Crivellari D， Gray KP， Dellapasqua S， et al. Adjuvant pegylatedliposomal doxorubicin for older women with endocrine nonrespo-nsive breast cancer who are not suitable for a “standard chemotherapy regimen”：the CASA randomized trial[J]. Breast， 2013，.
25.	Dellapasqua S， Colleoni M， Castiglione M， et al. New criteria for selecting elderly patients for breast cancer adjuvant treatment studies[J]. Oncologist， 2007， 12(8)：952-959.
26.	Leonard R， Ballinger R， Cameron D， et al. Adjuvant chemotherapy in older women (ACTION) study-what did we learn from the pilot phase?[J]. Br J Cancer， 2011， 105(9)：1260-1266.
27.	(8)：1177-1183.

1. Yancik R， Ries LA. Aging and cancer in America. Demographic and epidemiologic perspectives[J]. Hematol Oncol Clin North Am， 2000， 14(1)：17-23.
2. Hickey M， Peate M， Saunders CM， et al. Breast cancer in young women and its impact on reproductive function[J]. Hum Reprod Update， 2009， 15(3)：323-339.
3. 中國廣播網. 中國第六次人口普查[EB/OL]. http：//native. cnr. cn/list/201208/t20120810_510541842. html.
4. Althuis MD， Dozier JM， Anderson WF， et al. Global trends inbreast cancer incidence and mortality 1973-1997[J]. Int J Epid-emiol， 2005， 34(2)：405-412.
5. NCCN. Clinical Practice Guidelines in Oncology (NCCN Guidelines)-Breast Cancer[EB/OL]. http：//www.nccn. com/cancer-guidelines. html.
6. Brunello A， Basso U， Pogliani C， et al. Adjuvant chemotherapy for elderly patients (＞or=70 years) with early high-risk breast cancer：a retrospective analysis of 260 patients[J]. Ann Oncol， 2005， 16(8)：1276-1282.
7. 應紅艷，白春梅，管梅，等. 老年乳腺癌患者的臨床病理特點及治療影響因素[J]. 中國醫學科學院學報， 2010， 32(4)：398-402.
8. Holmes CE， Muss HB. Diagnosis and treatment of breast cancer in the elderly[J]. CA Cancer J Clin， 2003， 53(4)：227-244.
9. Office for National Statistics 2010-based period expectation of life， 1981-2060. United Kingdom：Principal Projection[EB/OL].http：//www. ons. gov. uk/ons/publications/re-referencetables. html?edition=tcm%3A77-227587.
10. 新年齡分段[EB/OL]. http：//baike. baidu. com/view/10593790. htm.
11. Muss HB， Berry DA， Cirrincione CT， et al. Adjuvant chemotherapy in older women with early-stage breast cancer[J]. N Engl J Med， 2009， 360(20)：2055-2065.
12. Muss HB， Woolf S， Berry D， et al. Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer[J]. JAMA， 2005， 293(9)：1073-1081.
13. Singh R， Hellman S， Heimann R. The natural history of breast carcinoma in the elderly：implications for screening and treatment[J]. Cancer， 2004， 100(9)：1807-1813.
14. Jung SP， Lee JE， Lee SK， et al. Adjuvant chemotherapy and survival of elderly korean patients with breast carcinoma[J]. J Breast Cancer， 2012， 15(3)：296-305.
15. Fargeot P， Bonneterre J， Roché H， et al. Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable， node-positive， elderly breast cancer patients：6-year follow-up results of the French adjuvant study group 08 trial[J]. J Clin Oncol， 2004， 22(23)：4622-4630.
16. Biganzoli L， Wildiers H， Oakman C， et al. Management of elderlypatients with breast cancer：updated recommendations of the Intern-ational Society of Geriatric Oncology (SIOG) and European Societyof Breast Cancer Specialists (EUSOMA)[J]. Lancet Oncol， 2012， 13(4)：148-160.
17. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival：an overview of the randomised trials[J]. Lancet， 2005， 365(9472)：1687-1717.
18. Giordano SH， Duan Z， Kuo YF， et al. Use and outcomes of adjuvant chemotherapy in older women with breast cancer[J]. J Clin Oncol， 2006， 24(18)：2750-2756.
19. Elkin EB， Hurria A， Mitra N， et al. Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer：assessing outcome in a population-based， observational cohort[J]. J Clin Oncol， 2006， 24(18)：2757-2764.
20. Debled M， Bellera C， Donamaria C， et al. Chemotherapy treatment for older women with metastatic breast cancer：what is the evidence?[J]. Cancer Treat Rev， 2011， 37(8)：590-598.
21. Jones S， Holmes FA， O’Shaughnessy J， et al. Docetaxel withcyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide：7-year follow-up of US Oncology Research Trial 9735[J]. J Clin Oncol， 2009，.
22. Ladoire S， Rambach L， Quipourt V， et al. Feasibility and safety of weekly sequential epirubicin-paclitaxel as adjuvant treatment for operable breast cancer patients older than 70 years[J]. Clin Breast Cancer， 2011， 11(4)：235-240.
23. (2)：130-137.
24. Crivellari D， Gray KP， Dellapasqua S， et al. Adjuvant pegylatedliposomal doxorubicin for older women with endocrine nonrespo-nsive breast cancer who are not suitable for a “standard chemotherapy regimen”：the CASA randomized trial[J]. Breast， 2013，.
25. Dellapasqua S， Colleoni M， Castiglione M， et al. New criteria for selecting elderly patients for breast cancer adjuvant treatment studies[J]. Oncologist， 2007， 12(8)：952-959.
26. Leonard R， Ballinger R， Cameron D， et al. Adjuvant chemotherapy in older women (ACTION) study-what did we learn from the pilot phase?[J]. Br J Cancer， 2011， 105(9)：1260-1266.
27. (8)：1177-1183.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Rethinking about Effect of Adjuvant Chemotherapy for Older Breast Cancer Patients

Abstract Full text Figures/Tables Video References Cited by

Format

Content